Researchers elucidate cause of death of photoreceptor cells in retinitis pigmentosa

Findings suggest new pathway as potential target for treatment of potentially blinding disease

22-Aug-2012 - USA

Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP). This groundbreaking study, led by Demetrios G. Vavvas, M.D., Ph.D., and including Joan W. Miller, M.D., Mass. Eye and Ear/Mass General Hospital Chief of ophthalmology and Chair of Ophthalmology at Harvard Medical School, has further identified the receptor interacting protein (RIP) kinase pathway as a potential target for developing treatment for vision loss in patients with retinitis pigmentosa. The study is published in the Proceedings of the National Academy of Sciences Early Edition.

Retinitis pigmentosa is an inherited condition that causes irreversible vision loss due to the degeneration of photoreceptor cells in the eye called "rods" and "cones." Rods are responsible for night vision, while cones are responsible for daylight and central vision. Vision loss from RP often begins with loss of night vision, due to death of rods, followed by loss of peripheral and central vision, due to death of rods and cones. Such vision loss can have a significant impact on people's daily lives, such as affecting their ability to read or drive a car. RP affects more than 1 million people around the world.

Research conducted by Eliot L. Berson, M.D., of the Berman-Gund Laboratory for the Study of Retinal Degenerations at Mass. Eye and Ear, has shown that Vitamin A supplementation and an omega-3 rich diet can slow visual decline resulting from RP; they do not completely stop disease progression, however. For most patients, RP results in irreversible vision loss.

Previous studies have identified mutations in more than 50 genes that cause RP, but the mechanisms by which rods and cones die remain to be completely defined. Since many of the genes associated with RP produce proteins that are used specifically in rod cells, it is still a puzzle why and how cones, which in some cases do not use the mutant proteins, die after rods degenerate. Using an animal model of RP, the investigators studied whether RIP kinase mediated necrosis is involved in the death of photoreceptor cells, finding for the first time that it is involved in cone degeneration and that a deficiency of RIP kinase reduced cone loss. Moreover, the study found that treatment with a drug that inhibits RIP kinase significantly delayed cone cell death and preserved cone photoreceptors.

"Though the precise mechanisms involved in RIP kinase inducing necrosis remain unknown, our finding that necrosis results in cone cell death puts us one step closer to understanding this disease and, more importantly, moves us one step closer to being able to provide novel therapies to millions of patients with vision loss," said Dr. Vavvas.

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

QIAGEN Enables Efforts to Eradicate Costly Cattle Disease - Collaboration with Swiss laboratory Microsynth AG pioneers nucleic acid-based primary screening for Bovine Viral Diarrhea

New screening tool could speed development of ovarian cancer drugs

Newfound link between Alzheimer’s and iron could lead to new medical interventions - What if amyloid beta plaques aren’t the main cause of Alzheimer’s disease?

Newfound link between Alzheimer’s and iron could lead to new medical interventions - What if amyloid beta plaques aren’t the main cause of Alzheimer’s disease?

UD signs commercialization agreement on corn disease trait

Snake venom could make surgery safer for patients on blood thinners

ORCA Therapeutics licenses oncolytic adenovirus technology from VCN Biosciences

Bentley Pharmaceuticals and the University of New Hampshire Announce Advances in Nanotechnology Research Program

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

Walter Reed Army Institute and Siam Life Science Develop New Gold Standard for Pharmacological and Toxicological Test Systems - Siam Life Science Secures Exclusive License For Unique Liver Cell Line From Walter Reed Army Institute Of Research

Artificial 'plants' could fuel the future

Novasep Appoints a New Chairman for its Supervisory Board - Bernard Dubois, Former Aventis Senior VP of Global Industrial Operations Brings a Wealth of Experience to Novasep's Top Management Team

Tumors backfire on chemotherapy

Tumors backfire on chemotherapy